FIELD: medicine; pharmacology.
SUBSTANCE: group of inventions relates to pharmacology, and can be used as stable pharmaceutical compositions based on antibodies. Disclosed is a stable antibody-based formulation containing a bispecific IL-4/IL-13 antibody or antigen-binding agent thereof, a buffer system which maintains pH 7 and mannitol. Concentration of salts in composition is 15 mM. Invention also discloses a stable lyophilized antibody-based formulation.
EFFECT: group of inventions provides stability of the lyophilized composition based on the IL-4/IL-13 antibody during preparation and storage thereof.
30 cl, 31 tbl, 8 ex, 34 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION | 2017 |
|
RU2775944C2 |
| IL-4 AND/OR IL-13 BINDING ANTIBODIES AND USING THEM | 2008 |
|
RU2580049C2 |
| METHOD FOR PURIFYING CONJUGATES BASED ON IL-15/IL-15Rα | 2015 |
|
RU2701301C2 |
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| COMPOSITIONS OF ANTIBODIES TO RSV AND METHODS OF THEIR APPLICATION | 2019 |
|
RU2807524C2 |
| MONOCLONAL ANTIBODY TO IL-5RΑ | 2017 |
|
RU2698048C2 |
| HIGHLY CONCENTRATED COMPOSITIONS OF ANTIBODIES TO C5 | 2018 |
|
RU2787595C2 |
| ANTIBODIES BINDING IL-4 AND/OR IL-13, AND USE THEREOF | 2015 |
|
RU2705551C2 |
| ANTIBODIES BINDING IL-4 AND/OR IL-13, AND THEIR USE | 2015 |
|
RU2721236C2 |
| ANTIBODIES BINDING IL-4 AND/OR BL-13 AND THEIR APPLICATION | 2008 |
|
RU2488595C2 |
